Cambridge Crossing, a burgeoning life sciences hub, recently attracted significant financial backing with a $341.3 million refinancing loan for its lab development at 441 Morgan Ave. This strategic funding will bolster DivcoWest’s ambitious project within the mixed-use campus.
Project Overview
The 372,000 square-foot laboratory facility currently features approximately 309,000 square feet available for lease. Astellas Pharma Inc. occupies about 62,000 square feet across two floors, highlighting the site’s appeal to major biotech firms. Additionally, the complex includes a 285-car parking garage designed to support both tenants and visitors.
Financing History
DivcoWest initially broke ground on the project in 2021, having secured a $401 million construction loan from KKR. The facility reached completion in 2024, marking a significant achievement in the life sciences sector amidst the challenges posed by the pandemic.
Market Dynamics
In the wake of COVID-19, DivcoWest, like many developers, recognized the growing demand for life sciences space and adapted its plans accordingly. In 2022, the company transitioned its vision for the 151 Morgan Ave. property from an office building to a life sciences facility, reflecting the evolving needs of the market.
The Mixed-Use Campus
The 43-acre Cambridge Crossing campus hosts several other life sciences buildings, including 121 Morgan Ave. and 222 Jacobs St. Collectively, these properties accommodate renowned pharmaceutical companies such as Bristol Myers Squibb, AbbVie, and Sanofi, solidifying the area’s reputation as a prime location for biotech innovation.
Campus Features
Cambridge Crossing boasts a total of 2.1 million square feet dedicated to office and life sciences space, alongside 2.4 million square feet of residential area and 11 acres of public space. Its strategic location near the Green Line’s Lechmere stop enhances accessibility, making it an attractive destination for professionals and residents alike.
Funding Challenges
Despite the financing success with the lab facility, DivcoWest faced hurdles in securing funding for two multifamily projects within the campus last year. The company paused these initiatives, attributing the decision to cautious lending practices and broader economic uncertainties linked to tariffs.
Outlook for Life Sciences
The refinanced loan reinforces Cambridge Crossing’s position in the dynamic life sciences landscape. As demand for innovative laboratory spaces continues to surge, this funding will enable DivcoWest to maintain its trajectory in developing a premier destination for biotech firms.
In conclusion, the successful refinancing of the Cambridge Crossing lab development underscores the resilience and adaptability of the life sciences sector. As the industry evolves, projects like this will play a crucial role in fostering innovation and collaboration among leading pharmaceutical companies.
- Cambridge Crossing secures $341.3M refinancing loan.
- Astellas Pharma occupies a significant portion of the lab space.
- The campus features multiple renowned pharma tenants.
- DivcoWest adapts to market demands amid economic challenges.
- The site includes extensive office, residential, and public spaces.
Read more → www.bisnow.com